Difficult-to-treat primary immune thrombocytopenia in adults: Prevalence and burden. Results from the CARMEN-France registry.
Br J Haematol
; 204(4): 1476-1482, 2024 Apr.
Article
en En
| MEDLINE
| ID: mdl-38267268
ABSTRACT
The aim of this study was to assess the prevalence and the burden of difficult-to-treat primary ITP (pITP), defined by the need for another ITP treatment after romiplostim and eltrombopag. Adult patients were selected in the prospective, real-world CARMEN-France registry up to December 2021. Out of 821 adult patients with pITP, 29 had difficult-to-treat ITP (3.5%; 95% confidence interval [CI] 2.3%-4.8% in total; 7.6%; 95% CI 4.9%-10.2% of patients needing ≥2nd line treatment). The 3-year cumulative incidence of bleeding, infection and thrombosis was 100%, 24.1% and 13.8% respectively. The median cumulative duration of hospital stays was 31 days (median follow-up 30.3 months).
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Púrpura Trombocitopénica Idiopática
Tipo de estudio:
Prevalence_studies
/
Risk_factors_studies
Límite:
Adult
/
Humans
País como asunto:
Europa
Idioma:
En
Año:
2024
Tipo del documento:
Article